CCN1 and plasma cell myeloma: Contrary to what observed for other CCN proteins and cancers, its expression positively correlates with better prognosis; consistent with its inhibitory role in osteoclastogenesis, exogenous administration of CCN1 to multiple myeloma cells in coculture with MSCs slows proliferation and bone resorption, favouring osteoblasts to the detriment of osteoclasts (Johnson et al. 2014; Liu et al. 2017a).